The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors

被引:28
|
作者
Pajarillo, Edward [1 ]
Rizor, Asha [1 ]
Lee, Jayden [2 ]
Aschner, Michael [3 ]
Lee, Eunsook [1 ]
机构
[1] Florida A&M Univ, Coll Pharm, Dept Pharmaceut Sci, Tallahassee, FL 32301 USA
[2] Boston Univ, Dept Speech Language & Hearing Sci, Boston, MA 02215 USA
[3] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
基金
美国国家卫生研究院;
关键词
alpha-Synuclein; LRRK2; Parkinson's disease; Manganese; Posttranslational modifications; REPEAT KINASE 2; N-TERMINAL ACETYLATION; IN-VITRO; DOPAMINERGIC NEURODEGENERATION; MITOCHONDRIAL DYSFUNCTION; DOMINANT PARKINSONISM; TYROSINE NITRATION; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; 14-3-3; BINDING;
D O I
10.1016/j.bbadis.2018.11.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD), and the most prevalent movement disorder. PD is characterized by dopaminergic neurodegeneration in the substantia nigra, but its etiology has yet to be established. Among several genetic variants contributing to PD pathogenesis, alpha-synuclein and leucine-rich repeat kinase (LRRK2) are widely associated with neuropathological phenotypes in familial and sporadic PD. alpha-Synuclein and LRRK2 found in Lewy bodies, a pathogenic hallmark of PD, are often posttranslationally modified. As posttranslational modifications (PTMs) are key processes in regulating the stability, localization, and function of proteins, PTMs have emerged as important modulators of alpha-synuclein and LRRK2 pathology. Aberrant PTMs altering phosphorylation, ubiquitination, nitration and truncation of these proteins promote PD pathogenesis, while other PTMs such as sumoylation may be protective. Although the causes of many aberrant PTMs are unknown, environmental risk factors may contribute to their aberrancy. Environmental toxicants such as rotenone and paraquat have been shown to interact with these proteins and promote their abnormal PTMs. Notably, manganese (Mn) exposure leads to a PD-like neurological disorder referred to as manganism-and induces pathogenic PTMs of alpha-synuclein and LRRK2. In this review, we highlight the role of PTMs of alpha-synuclein and LRRK2 in PD pathogenesis and discuss the impact of environmental risk factors on their aberrancy.
引用
收藏
页码:1992 / 2000
页数:9
相关论文
共 50 条
  • [41] Identification of LRRK2 mutations in Parkinson's disease
    Lewthwaite, A. J.
    Nicholl, D. J.
    Morrison, K. E.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (12): : 1397 - 1397
  • [42] LRRK2 at the Crossroad of Aging and Parkinson's Disease
    Hur, Eun-Mi
    Lee, Byoung Dae
    GENES, 2021, 12 (04)
  • [43] Analysis of LRRK2 variants in Parkinson's disease
    Au, W. L.
    Ho, P.
    Zhao, Y.
    Tan, L. C. S.
    Tan, E. K.
    MOVEMENT DISORDERS, 2010, 25 (07) : S468 - S468
  • [44] LRRK2 is reduced in Parkinson’s disease gut
    Adrien de Guilhem de Lataillade
    Jérémy Verchere
    Thibauld Oullier
    Alice Prigent
    Tony Durand
    Carolina Pellegrini
    Michel Neunlist
    Thierry Baron
    Malvyne Rolli-Derkinderen
    Pascal Derkinderen
    Acta Neuropathologica, 2021, 142 : 601 - 603
  • [45] Mutations in LRRK2 as a cause of Parkinson's disease
    Giasson, Benoit I.
    Van Deerlin, Vivianna M.
    NEUROSIGNALS, 2008, 16 (01) : 99 - 105
  • [46] LRRK2, lysosome damage, and Parkinson's disease
    Bentley-DeSousa, Amanda
    Clegg, Devin
    Ferguson, Shawn M.
    CURRENT OPINION IN CELL BIOLOGY, 2025, 93
  • [47] Environmental Factors are Associated with Disease Severity of LRRK2 Related Parkinson's disease (PD) and Idiopathic Parkinson's disease (PD) : a Longitudinal Study
    Lueth, T.
    Caliebe, A.
    Gabbert, C.
    Koch, S.
    Laabs, B. -H.
    Koenig, I. R.
    Klein, C.
    Trinh, J.
    MOVEMENT DISORDERS, 2024, 39 : S216 - S216
  • [48] The Cell Biology of LRRK2 in Parkinson's Disease
    Usmani, Ahsan
    Shavarebi, Farbod
    Hiniker, Annie
    MOLECULAR AND CELLULAR BIOLOGY, 2021, 41 (05)
  • [49] LRRK2 is reduced in Parkinson's disease gut
    de Guilhem de Lataillade, Adrien
    Verchere, Jeremy
    Oullier, Thibauld
    Prigent, Alice
    Durand, Tony
    Pellegrini, Carolina
    Neunlist, Michel
    Baron, Thierry
    Rolli-Derkinderen, Malvyne
    Derkinderen, Pascal
    ACTA NEUROPATHOLOGICA, 2021, 142 (03) : 601 - 603
  • [50] Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications
    Qing, Hong
    Wong, Winnie
    McGeer, Edith G.
    McGeer, Patrick L.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 387 (01) : 149 - 152